SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM), today announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully ...
Tandem Diabetes Care has received the Food and Drug Administration’s green light for the Tandem Mobi insulin pump for people with diabetes aged 6 years old and older. The Tandem Mobi is fully ...
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration (FDA) clearance for ...
The U.S. Food and Drug Administration has classified a corrective action involving insulin pumps from Tandem Diabetes Care Inc. TNDM as a Class I recall, the agency's most serious designation, citing ...
Tandem Diabetes Care, Inc.’s TNDM Mobi insulin pump with Control-IQ technology is now fully compatible with both Dexcom’s DXCM G7 and G6 Continuous Glucose Monitoring (“CGM”) Systems. The world’s ...
The FDA has classified a corrective action for Tandem Diabetes Care’s Mobi insulin pumps as a Class I recall, its highest risk category, due to a defect that can halt insulin delivery and cause ...
After a successful limited rollout of its newest insulin pump in the U.S., Tandem Diabetes Care is picking up the pace. The Mobi pump will now begin a widespread national launch, with Tandem already ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results